<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Vinall, Maria</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Bhatt, Deepak L.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">The Evolving Science and Treatment of Thrombosis</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2010</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2010-02-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">6-7</style></pages><abstract><style  face="normal" font="default" size="100%">A number of promising new antithrombotic agents intended to prevent atherothrombotic events in patients with coronary artery disease (CAD) and atrial fibrillation are currently being investigated. This article discusses the progress that is being made with adenosine diphosphate (ADP) inhibitors, antithrombins and factor Xa inhibitors. Other topics include the the problem of stent thrombosis and possible solutions.</style></abstract><number><style face="normal" font="default" size="100%">6</style></number><volume><style face="normal" font="default" size="100%">9</style></volume></record></records></xml>